The effects of vildagliptin compared with metformin on vascular endothelial function and metabolic parameters: a randomized, controlled trial (Sapporo Athero-Incretin Study 3)

Dipeptidyl peptidase-4 (DPP-4) inhibitors may have protective effects in the early stage of atherosclerosis in patients with type 2 diabetes, although similar effects in advanced atherosclerosis were not shown...
Source: Cardiovascular Diabetology - Category: Cardiology Authors: Tags: Original investigation Source Type: research

Related Links:

In conclusion, the data identified the IRE1α-Xbp1 signaling pathway as an essential mediator that associates EX-4 with the intracellular mechanism that inhibits ER stress and activates Akt in order to regulate β cell survival. This may provide important evidence for the use of EX-4 in treatments for type 2 diabetes. PMID: 30112049 [PubMed]
Source: Experimental and Therapeutic Medicine - Category: General Medicine Tags: Exp Ther Med Source Type: research
ConclusionFor poorly controlled T2DM on DPP-4i-based OAD therapy, switching to single-dose liraglutide to enhance incretin signaling is as effective as dose-titrated basal IGlar, but significant BW reduction was only seen in the liraglutide group. These results suggest that enhancing incretin signaling with a single-dose injectable GLP-1 RA might be an alternative to dose-titrated basal insulin therapy in patients with T2DM poorly controlled with DPP-4i-based OAD therapy. These findings should be confirmed in a longer and larger trial.Trial RegistrationTrial Registry (UMIN-CTR) as UMIN000012224.
Source: Diabetes Therapy - Category: Endocrinology Source Type: research
To the Editor Inge et al have shown that bariatric surgery has a greater association than medical treatment alone in achieving an improvement of type 2 diabetes mellitus and its comorbidities in obese adolescents. The mechanism seems to go beyond the magnitude of weight loss alone and include an improvement in incretin profiles, insulin secretion, and insulin sensitivity.
Source: JAMA Pediatrics - Category: Pediatrics Source Type: research
Publication date: Available online 10 August 2018Source: Diabetes &Metabolic Syndrome: Clinical Research &ReviewsAuthor(s): Ala'a G. Almagthali, Eman H. Alkhaldi, Afnan S. Alzahrani, Ameera K. Alghamdi, Waleed Y. Alghamdi, Ahmed M. KabelAbstractDipeptidyl peptidase (DPP- 4) inhibitors belong to the oral antidiabetic drugs. They are used for the treatment of Type 2 Diabetes mellitus. DPP-4 is an enzyme which puts down the action of hormone, incretin. Incretins belong to the group of hypoglycaemic gastrointestinal hormones. Some studies show that DPP-4 inhibitors causes cancer and some study show that they have antic...
Source: Diabetes and Metabolic Syndrome: Clinical Research and Reviews - Category: Endocrinology Source Type: research
Ah-Reum Han Dipeptidyl peptidase IV (DPP-IV), a new target for the treatment of type 2 diabetes mellitus, degrades incretins such as glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide. DPP-IV inhibitors shorten the inactivation of GLP-1, permitting the incretin to stimulate insulin release, thereby combating hyperglycemia. In our ongoing search for new DPP-IV inhibitors from medicinal plants and foods, three flavonol glycosides (1–3) were isolated from the seeds of Lens culinaris Medikus (Fabaceae) and tested for their DPP-IV–inhibitory activity. We demonstrated for the...
Source: Molecules - Category: Chemistry Authors: Tags: Communication Source Type: research
This article summarizes the current evidence for the safety and efficacy of alogliptin and metformin used in combination for the treatment of type 2 diabetes mellitus. PMID: 30063448 [PubMed]
Source: Expert Review of Endocrinology and Metabolism - Category: Endocrinology Tags: Expert Rev Endocrinol Metab Source Type: research
Authors: Schernthaner-Reiter MH, Schernthaner G Abstract Type 2 diabetes mellitus (T2DM) is a growing health problem worldwide; its pathogenesis is multifactorial and its progressive nature often necessitates a combination therapy with multiple antihyperglycemic agents. Sodium glucose cotransporter 2 (SGLT2) inhibitors and the incretin-based therapies - dipeptidyl peptidase 4(DPP-4) inhibitors and glucagon-like peptide 1 (GLP-1) receptor agonists - were introduced for the treatment of T2DM within the last decade. Evidence of the beneficial effects of these antihyperglycemic agents on micro- and macrovascular compli...
Source: Expert Review of Endocrinology and Metabolism - Category: Endocrinology Tags: Expert Rev Endocrinol Metab Source Type: research
CONCLUSIONS: Overall, incretin-based therapies were well tolerated; however, their long-term safety profile should continue to be periodically assessed. PMID: 30058866 [PubMed]
Source: Expert Review of Endocrinology and Metabolism - Category: Endocrinology Tags: Expert Rev Endocrinol Metab Source Type: research
Aim: Metformin (MET) is a 1st choice drug for treatment of type 2. Diabetes (DM), its use in patients with heart failure (HF) patients is associated with lower frequency of cardiovascular events and with better survival, but mechanisms are unexplained.
Source: Atherosclerosis - Category: Cardiology Authors: Source Type: research
Obesity and type 2 diabetes mellitus (T2DM) have become a substantial burden on public health in the last century and advocate different strategies to mitigate them [1]. Proximal small bowel diversion bears prominent beneficial metabolic effects associated with augmentation of the incretin system and accelerated glucose handling in the distal part of the gut [2, 3]. Roux-en-Y gastric bypass (RYGB) surgery exhibits these advantages [4 –6] and is an effective tool for weight reduction and glycemic control [7].
Source: Surgery for Obesity and Related Diseases - Category: Surgery Authors: Tags: Original articles Source Type: research
More News: Cardiology | Cardiovascular | Diabetes | Diabetes Type 2 | Endocrinology | Fortamet | Heart | Incretin Therapy | Metformin | Study